Aptiv to Release Third Quarter 2024 Financial Results
Aptiv to Release Third Quarter 2024 Financial Results
Aptiv PLC (NYSE: APTV), will release its third quarter 2024 financial results on October 31, 2024 and will hold an investor call the same day at 8:00 a.m. EDT. The call will be hosted by Aptiv's Chairman and Chief Executive Officer, Kevin Clark, and Vice Chairman, Business Operations and Chief Financial Officer, Joseph Massaro.
A link to the live webcast and presentation materials will be available on the Aptiv Investor Relations website at ir.aptiv.com. A replay will be available two hours following the conference call.
To participate by telephone, please dial 800-239-9838 (U.S.) or +1 323-994-2093 (international) 15 minutes prior to the start of the call and ask to be connected to the Aptiv PLC conference call. The conference ID number is 1329199.
About Aptiv
Aptiv is a global technology company that develops safer, greener and more connected solutions enabling a more sustainable future of mobility. Visit aptiv.com.
Investor Relations Contact
Jane Wu
Vice President, Investor Relations & Corporate Development
jane.wu@aptiv.com
Media Relations Contact
mediarelations@aptiv.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927155760/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks